



SCIENTIFIC PROGRAM



NINTH MENACTRIMS CONGRESS FRIDAY, NOVEMBER 1, 2024 MAIN HALL

08:00-09:00 Registration & Morning Coffee

09:00-10:00

Session I: MS Diagnosis
Chairs: M. Al-Jumrah (SA) & R. Gouider (TN)

09:00-09:25	Optic Neuritis: Differential Diagnosis and Paraclinical Tools	F. Althekair (SA)
09:25-09:50	The New 2024 McDonald Criteria	B. Yamout (AE)
09:50-10:00	<i>Panel Discussion</i>	
10:00-10:15	Coffee Break	

10:15-10:45

Matters of our Time: Unlocking the Full Potential of a CD20 Therapy
hosted by Roche
Chair: B. Yamout (AE)

10:15-10:20	Welcome	B. Yamout (AE)
10:20-10:25	Long term Efficacy of Ocrelizumab	Y. Al Malik (SA)
10:25-10:30	Long term Safety of Ocrelizumab	R. Alroughani (KW)
10:30-10:35	Convenience of Ocrelizumab SC	M. Maeurer (DE)
10:35-10:45	<i>Panel Discussion</i>	

10:45-11:45

Session II: Biomarkers in MS
Chairs: R. Alroughani (KW) & Y. Al Malik (SA)

10:45-11:10	Monitoring MS with Blood Biomarkers: Are We There Yet?	J. Kuhle (CH)
11:10-11:35	New Imaging Biomarkers in MS: CVS, SEL and PRL	C. Granziera (CH)
11:35-11:45	<i>Panel Discussion</i>	
11:45-13:15	Friday Prayer Break and Lunch	

13:15-14:30

Session III: MS Treatment
Chairs: J. Inshasi (AE) & N. Grigoriadis (GR)

13:15-13:35	Women and MS: What is New?	K. Hellwig (DE)
13:35-13:55	Update on New Therapies in MS	M. Tintore (ES)
13:55-14:15	Neuroprotection in MS: Is it Currently Achievable?	B. Stankoff (FR)
14:15-14:30	<i>Panel Discussion</i>	



SCIENTIFIC PROGRAM



NINTH MENACTRIMS CONGRESS FRIDAY, NOVEMBER 1, 2024 MAIN HALL

14:30-14:45 Welcome and Introduction by B. Yamout (AE), President of MENACTRIMS		
14:45-15:15 Transforming Treatment Paradigms in Multiple Sclerosis hosted by Novartis Chair: H. Alnajashi (SA)		
14:45-14:50	Welcome	H. Alnajashi (SA)
14:50-15:00	Importance of Starting with HETs Early in Disease Course	C. Oreja-Guevara (ES)
15:00-15:10	Transforming Treatment Paradigm in MS with Ofatumumab	C. Oreja-Guevara (ES)
15:10-15:15	Panel Discussion	
15:15-15:30	Coffee Break	
15:30-16:00 Cladribine Throughout the Therapeutic Pathway hosted by Merck Chairs: M. Al-Jumma (SA)		
15:30-15:33	Welcome	M. Al-Jumma (SA)
15:33-15:45	Cladribine tablets: A Focus on the Neuroimmunological Effects	P. Vermersch (FR)
15:45-15:57	Optimizing Long-term Management in MS: Balancing Continued Treatment Burden with Outcomes	G. Giovannoni (UK)
15:57-16:00	Concluding Remarks	M. Al-Jumma (SA)
16:00-17:00 Session IV: Update on Progressive MS Chairs: M. Zakaria (EG) & A. Siva (TR)		
16:00-16:25	Do We Need to Drop the Term Progressive MS?	G. Giovannoni (UK)
16:25-16:50	How to Assess PIRA in MS	E. Hamdy (EG)
16:50-17:00	Panel Discussion	



SCIENTIFIC PROGRAM



NINTH MENACTRIMS CONGRESS FRIDAY, NOVEMBER 1, 2024 MAIN HALL

17:00-18:00 Session V: Oral Presentations <i>Chairs: M. Al-Jumma (SA) & A. Jacob (AE)</i>		
17:00-17:10	Experience with Autologous Stem Cell Transplant in Multiple Sclerosis in the UAE	L. Brylev (AE)
17:10-17:20	The Comparative Effectiveness of Natalizumab and Anti-CD20 Monoclonal Antibodies in Relapsing-Remitting Multiple Sclerosis: A Real-World based Study	B. Yamout (AE)
17:20-17:30	Cerebrospinal Fluid and Serum Neurofilament Light Chain Levels at Baseline Predict Disease Activity and Severity in Neuromyelitis Optica Spectrum Disorder Patients	S. Mrabet (TN)
17:30-17:40	Diagnostic Utility of the Central Vein Sign in Multiple Sclerosis with Implementation of the 6 Lesion Rule	S. Alsalamah (SA)
17:40-17:50	Outcome of Multiple Sclerosis with and without Optic Neuritis	A. Abulaban (SA)
17:50-18:00	Quantitative Susceptibility Mapping (QSM)-based Regional Iron Concentration: Does it Correlate with Brain Volume Loss? An Analysis of 250 Regions of Interest (ROIs)	E. Hamdy (EG)
19:30-22:30 Congress Dinner at Park Hyatt <i>(by ticket only- last buses depart at 19:00 from Hilton Hotel Lobby)</i>		



SCIENTIFIC PROGRAM



NINTH MENACTRIMS CONGRESS SATURDAY, NOVEMBER 2, 2024 MAIN HALL

08:00-09:00 Registration & Morning Coffee

Session VI: Updates in MS <i>Chairs: S. Bohlega (SA) & M.A. Sahraian (IR)</i>		
09:00-10:15		
09:00-09:20	Anti CD20s Extended Interval Dosing: Is it the Future?	S. Khoury (LB)
09:20-09:40	How to Interpret Statistics in MS Studies	M. Sormani (IT)
09:40-10:00	Disparities in MS Care and Treatment: Clinical and Ethnic Considerations	J. Al Khaboori (OM)
10:00-10:15	<i>Panel Discussion</i>	
10:15-10:30	Coffee Break	
Advancements in Multiple Sclerosis: Bridging Science and Clinical Practice hosted by Sanofi <i>Chair: J. Inshasi (AE)</i>		
10:30-11:00		
10:30-10:40	From Cells to Symptoms: The Biological Basis of Progression in MS	R. Alroughani (KW)
10:40-10:50	Latest Discoveries in Multiple Sclerosis: A Look to the Future	R. Alroughani (KW)
10:50-11:00	<i>Panel Discussion</i>	
Session VII: EUROPEAN CHARCOT FOUNDATION The Patient at the Center: The Role of Patient Reported Outcomes <i>Chairs: G. Comi (IT) & M. Alkhwajjah (SA)</i>		
11:00-12:15		
11:00-11:20	Patient Reported Outcomes in Assessing Treatment Response	G. Comi (IT)
11:20-11:40	PROMS: Recent Developments and Future Perspectives	P. Vermersch (FR)
11:40-12:00	Remote Monitoring in PROMS: The Mobilise Study	L. Leocani (IT)
12:00-12:15	<i>Panel Discussion</i>	
Complement as a Therapeutic Target in NMOSD: From Clinical Evidence to Real World Experience hosted by AstraZeneca <i>Chair: R. Alroughani (KW)</i>		
12:15-12:45		
12:15-12:30	The Real Burden of NMOSD	Y. Al Malik (SA)
12:30-12:40	Complement as a Therapeutic Target: Real World Experience	S. Aljarallah (SA)
12:40-12:45	<i>Panel Discussion</i>	



SCIENTIFIC PROGRAM



NINTH MENACTRIMS CONGRESS SATURDAY, NOVEMBER 2, 2024 MAIN HALL

12:45-14:00 Lunch Break

14:00-15:15 **Session VIII: NMOGD and MOGAD** *Chairs: A. Mahdawi (IQ) & S. Aljarallah (SA)*

14:00-14:20 MRI Features Differentiating MS from NMOGD and MOGAD N. De Stefano (IT)

14:20-14:40 NMOGD: Update on Diagnosis and Treatment S. Makkawi (SA)

14:40-15:00 MOGAD: Diagnostic Criteria and Therapeutic Options A. Obeidat (US)

15:00-15:15 *Panel Discussion*

15:15-15:45 **New Heights of Efficacy and Flexibility with Natalizumab** **hosted by Biogen** *Chair: M. Alkhawajah (SA)*

15:15-15:35 New Heights of Efficacy and Flexibility with Natalizumab P. Vermersch (FR)

15:35-15:45 *Panel Discussion*

15:45-16:00 Coffee Break

16:00-17:15 **Session IX: Hot Topics in MS** *Chairs: M. Dahdaleh (JO) & C. Oreja-Guevara (ES)*

16:00-16:20 Familial MS in the MENA Region H. Hassoun (IQ)

16:20-16:40 Artificial Intelligence in MS D. Ontaneda (US)

16:40-17:00 The Year in MS: 2024 Highlights N. Bin Ali (TN)

17:00-17:15 *Panel Discussion*

17:15-17:45 **Closing Ceremony and Abstract Awards Presentation** *by B. Yamout (AE), President of MENACTRIMS*



SCIENTIFIC PROGRAM



NURSING SESSION SATURDAY, NOVEMBER 2, 2024 MAIN HALL

09:00-10:15		
Session I <i>Chair: J. Massouh (AE)</i>		
09:00-09:30	Clinical Nurse Practitioners: Essential Role in Diagnosis and Management of MS	F. Pastore (IT)
09:30-10:00	Women's Health in MS: Pregnancy Planning and Breastfeeding	S. Mekkawi (SA)
10:00-10:15	<i>Panel Discussion</i>	
10:15-10:30	Coffee Break	
10:30-12:45		
Session II <i>Chair: J. Massouh (AE)</i>		
10:30-11:00	DMTs: The Era of Too Many Choices	M. Zeineddine (LB)
11:00-11:30	Unmet Needs and Health Literacy in People with MS	F. Pastore (IT)
11:30-12:00	Cognition and Brain Health in MS	A. Obeidat (US)
12:00-12:30	Comprehensive Approach to Meeting the Needs of PwMS: Catalanian Expert Patient Program	M. A. Robles-Sanchez (ES)
12:30-12:45	<i>Panel Discussion</i>	
12:45-14:00	Lunch Break	
14:00-14:30		
Nursing Satellite Symposium I hosted by Novartis <i>Chair: R. Aldossary (SA)</i>		
14:00-14:30	Optimizing Patients Outcomes with Ofatumumab	A. Almutlaq (SA)
14:30-15:00		
Nursing Satellite Symposium II hosted by Roche Bridging Efficacy and Convenience: A Nurse's Guide to Ocrelizumab SC Administration <i>Chair: O. Salih (SA)</i>		
14:30-14:40	Overview of OCR SC	S. Kocak (DE)
14:40-14:45	How to Inject!	S. Kocak (DE)
14:45-15:00	<i>Group Workshop to Practice</i>	



SCIENTIFIC PROGRAM



NURSING SESSION SATURDAY, NOVEMBER 2, 2024 MAIN HALL

15:00-15:30	Nursing Satellite Symposium III hosted by AstraZeneca	
15:00-15:15	NMOSD Real Burden	J. Massouh (AE)
15:15-15:30	Role of Complement in NMOSD	G. Lee (AE)
15:30-16:00	Nursing Satellite Symposium IV hosted by Sanofi Early Indicators: A Nurse's Role in Detecting Subtle MS Progression	
15:30-16:00	Clinical Cases, Smoldering Neuroinflammation, & Clinical Assessment	M. Angel Robles (ES)
16:00-16:30	Nursing Satellite Symposium V hosted by Merck	
16:00-16:15	Early Intervention in Multiple Sclerosis: A Critical Approach for Optimizing Treatment Outcomes in Nursing Practice	S. Makkawi (SA)
16:15-16:30	Administration and Monitoring Burden of DMTs	S. Makkawi (SA)
16:30-17:00	Nursing Satellite Symposium VI hosted by Biogen Chair: H. Kedah (SA)	
16:30-17:00	Measuring Novel Efficacy Endpoints and Convenience with Tysabri SC	O. M. Nazmi (SA)